The Manges

BrainScope Receives Investment from the Alzheimer’s Drug Discovery Foundation for Alzheimer's Prediction Biomarker

Retrieved on: 
Tuesday, September 19, 2023
Research, Nursing, Medical Devices, Medical Supplies, Hospitals, FDA, Biotechnology, Health, Science, Other Science, Weil, Concussion, CT, ABS Capital Partners, IDEC, Northwell Health, General partnership, Medicine, Brain, Biomarker, BrainScope Company, Inc., Weil, Gotshal & Manges, Aria, The Manges, MRI, Traction, Patient, AbbVie, Stanford University Medical Center, Machine learning, Rituximab, Artificial intelligence, Sport, Johns Hopkins, Trauma, ALS, Ibrutinib, Computer security, Medical imaging, Pharmaceutical industry, Biogen, Pharmacyclics

Brain diagnostics innovator BrainScope announced today a new investment from the Alzheimer’s Drug Discovery Foundation (ADDF) in BrainScope’s current Series B equity financing round.

Key Points: 
  • Brain diagnostics innovator BrainScope announced today a new investment from the Alzheimer’s Drug Discovery Foundation (ADDF) in BrainScope’s current Series B equity financing round.
  • This investment supports the ongoing development of a new Artificial Intelligence / Machine Learning derived brain-activity based biomarker to predict future onset of Alzheimer’s.
  • "The global market for Alzheimer’s disease treatments is expected to rise to over $13 billion by 2030.
  • BrainScope also announced the appointment of three prominent individuals to its Board of Directors: Michael A. Epstein, Richard A. Miller MD, and Ralph Terkowitz.

FIVE ARROWS ACQUIRES MAJORITY STAKE IN N2Y

Retrieved on: 
Tuesday, April 4, 2023
Educational technology, Learning, Communication, Software as a service, Senior, Education, Arrows, Culture, Partner, Parent, Kagawa Five Arrows, Rothschild, Providence Equity, Weil, Gotshal & Manges, Rothschild & Co, School, Student, FAPI, FALT, Growth, IEP, IDEA, Tutoring, Management, The Manges, 1:32 scale

HURON, Ohio, April 4, 2023 /PRNewswire/ -- n2y, provider of comprehensive, technology–powered solutions for students with unique learning challenges, today announced it has entered into an agreement to be acquired by Five Arrows, the alternative assets arm of Rothschild & Co. n2y is the inaugural deal for Five Arrows Long Term Fund ("FALT" ) which has invested alongside Five Arrows Principal Investments ("FAPI"), together "Five Arrows". Five Arrows targets category-leading B2B data and software sectors across a focused set of end-markets including education and healthcare, with a long history of investing specifically in companies addressing the learning disabilities and special needs space in both Europe and North America. Five Arrows will become the majority shareholder and Providence Equity Partners will retain a minority equity stake. The terms of the transaction were not disclosed.

Key Points: 
  • Five Arrows will become the majority shareholder and Providence Equity Partners will retain a minority equity stake.
  • We're thrilled that Five Arrows believes in n2y's mission and wants to further our impact across the U.S. and beyond," said Ed Holmes, CEO of n2y.
  • "We look forward to teaming up with Five Arrows to help n2y expand its support for unique learners wherever they are."
  • Robert W. Baird & Co.  served as financial advisor to n2y with Weil, Gotshal & Manges acting as legal advisor on the transaction.

Microvast Announces Appointment of New Executive Officers

Retrieved on: 
Tuesday, April 19, 2022
Utilities, Other Manufacturing, Hardware, Energy, Technology, Automotive Manufacturing, Manufacturing, Other Technology, CIS, Weil, Gotshal & Manges, College, NASDAQ, Rudolf Kelterborn, LinkedIn, Vossloh, Marketing, University, Accounting, Emerging market, DLA Piper, Petron Corporation, Treasury, Ashmore Group, CPE, Private Securities Litigation Reform Act, General counsel, Board of directors, The Manges, Company, Solution, University of Stirling, BTS Group Holdings, Board, York, Twitter, Leadership, Piper, CFO, Growth, Communication, Savonia University of Applied Sciences, DLA, Industry, LPC, Sasha (name), BTS, Management, BKK

During Mr. Zhengs tenure, Microvast significantly expanded its scale and scope, culminating in a business combination to become a publicly-traded company.

Key Points: 
  • During Mr. Zhengs tenure, Microvast significantly expanded its scale and scope, culminating in a business combination to become a publicly-traded company.
  • This includes his tremendous leadership in transitioning Microvast from a privately held company to a publicly listed company, said Microvasts Chairman, Chief Executive Officer and founder, Yang Wu.
  • He previously served as the Chief Revenue Officer of Microvast, Inc. and Managing Director of Microvast EMEA since February 2021.
  • He has also served as Managing Director of Microvast Power Systems Co., Ltd. and of Microvast EMEA since June 2017.

LenioBio closes its Series-A Extension round and strengthens its Board of Directors

Retrieved on: 
Monday, March 7, 2022
Alice, Innovation, London Business School, Investment, University, Research, Access Industries, CFO, New Board, University of West London, Credit Suisse, LinkedIn, Board of directors, Growth, Sutro Biopharma, Series, Bocconi University, JPMorgan Chase, Board, Multimedia, Biotechnology, City University, KPMG, TMT, CEO, Gesellschaft mit beschränkter Haftung, Weil, Gotshal & Manges, Protein, Technology, BA, Sylvan Gotshal, The Manges, Management, Fine chemical

Along with the investment round, LenioBio strengthens its Non-executive Board of Directors.

Key Points: 
  • Along with the investment round, LenioBio strengthens its Non-executive Board of Directors.
  • New Board members include Dr. Remberto Martis, founder and CEO, Thomas Harding, Leopoldo Zambeletti and Karen Fallen.
  • With the new Board composition, LenioBio is well positioned to achieve the next stage on our journey."
  • LenioBio launched the ALiCE platform in October 2018 as an expression kit that outperforms its competitors in a single step.

LenioBio closes its Series-A Extension round and strengthens its Board of Directors

Retrieved on: 
Monday, March 7, 2022
Alice, Innovation, London Business School, Investment, University, Research, Access Industries, CFO, New Board, University of West London, Credit Suisse, LinkedIn, Board of directors, Growth, Sutro Biopharma, Series, Bocconi University, JPMorgan Chase, Board, Biotechnology, City University, KPMG, TMT, CEO, Gesellschaft mit beschränkter Haftung, Weil, Gotshal & Manges, Protein, Technology, BA, Sylvan Gotshal, The Manges, Management, Fine chemical

DÜSSELDORF, Germany, March 7, 2022 /PRNewswire/ -- LenioBio GmbH, a German life sciences biotech offering a disruptive protein manufacturing technology, ALiCE®, closed its Series-A Extension round with a total investment volume of €11.5 million. The investment round, which was closed in November 2021, is led by LenioBio's current investor Bridford Group, a PE investor focusing on founder-led businesses with long-term growth potential and concerned with societal or environmental welfare.

Key Points: 
  • LenioBio closes its Series-A Extension round with the current investor Bridford Group and strengthens its Board of Directors.
  • DSSELDORF, Germany, March 7, 2022 /PRNewswire/ --LenioBio GmbH, a German life sciences biotech offering a disruptive protein manufacturing technology, ALiCE, closed its Series-A Extension round with a total investment volume of 11.5 million.
  • Along with the investment round, LenioBio strengthens its Non-executive Board of Directors.
  • With the new Board composition, LenioBio is well positioned to achieve the next stage on our journey."

ZEDRA to Receive Strategic Minority Investment From BCI

Retrieved on: 
Wednesday, March 2, 2022
Banking, Other Professional Services, Professional Services, Finance, Lazard, Weil, Gotshal & Manges, Health, Knowledge, Corporate services, Solution, Growth, TMT, Acquisition, Simpson Thacher & Bartlett, Crown corporations of Canada, Technology, BCI, Insurance, Partnership, The Manges, Private equity, Financial services, Corsair, ZEDRA, Corsair, BCI, ZEDRA, CORSAIR, BCI

ZEDRA (ZEDRA or the Company), a global specialist in Global Expansion and Corporate Services, Active Wealth and Fund Solutions, today announced it has reached an agreement to receive a strategic minority investment from British Columbia Investment Management Corporation (BCI), one of Canadas largest institutional investors.

Key Points: 
  • ZEDRA (ZEDRA or the Company), a global specialist in Global Expansion and Corporate Services, Active Wealth and Fund Solutions, today announced it has reached an agreement to receive a strategic minority investment from British Columbia Investment Management Corporation (BCI), one of Canadas largest institutional investors.
  • Raja Hadji-Touma, Partner at Corsair, said, We are grateful for our successful partnership with the ZEDRA team and are delighted to welcome BCI as an investor alongside us.
  • This investment is a testament to ZEDRAs continued success executing on its growth plan, demonstrated by the Companys impressive team, product and geographical strategic expansion.
  • With C$199.6 billion of assets under management as of March 31, 2021, British Columbia Investment Management Corporation (BCI) is one of Canadas largest institutional investors.

Ardian Acquires Majority Stake in Florida Food Products and Forms Partnership With MidOcean

Retrieved on: 
Tuesday, September 21, 2021
Retail, Professional Services, Food, Beverage, Finance, The Manges, Partnership, Drink, Food, Investment, MidOcean Partners, Multimedia, Clos, Real estate, Ownership, Entrepreneurship, Heart, FFP, CEO, Acquisition, Company, Growth, Eileen M. Decker, Weil, Gotshal & Manges, Consumer, Financial services, Video game, Financial adviser

Ardian , a world-leading private investment house, announced today that it has acquired a majority stake in Florida Food Products ( FFP or the Company) through its U.S.

Key Points: 
  • Ardian , a world-leading private investment house, announced today that it has acquired a majority stake in Florida Food Products ( FFP or the Company) through its U.S.
  • MidOcean initially invested in the business in 2018 and will retain a significant stake in FFP alongside Ardian.
  • Thibault Basquin, Head of Americas Investments at Ardian Buyout stated, FFP plays a critical role in the development and formulations of clean label food products for todays consumer.
  • Florida Food Products is an impressive organization with tremendous growth opportunities and a wide range of capabilities, reflecting the successful implementation of MidOcean and managements ambitious growth strategy.

Walgreens Boots Alliance Makes Majority Investment in Shields Health Solutions, Expanding Position in Fast-Growing Specialty Pharmacy Market

Retrieved on: 
Tuesday, September 21, 2021
Professional Services, Managed Care, Other Health, Health, General Health, Specialty, Seniors, Pharmaceutical, Retail, Consumer, Finance, The Manges, Walgreens Boots Alliance, Welsh, Carson, Anderson & Stowe, Partnership, WCAS, Risk, Pharmacy, Annual report, Security (finance), Health, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Patient, Ownership, Board, FORTUNE, CEO, Industry, National Healthcare Group, Growth, Ropes & Gray, World, Sidley Austin, Centerview Partners, Participation, Traction, Research, Hart–Scott–Rodino Antitrust Improvements Act, Weil, Gotshal & Manges, United Nations Global Compact, Investment, General partnership, Quality of life, Nasdaq, WBA, Health insurance, Walgreens Boots Alliance, Shields Health Solutions, WALGREENS BOOTS ALLIANCE, SHIELDS HEALTH SOLUTIONS

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) and Shields Health Solutions today announced that WBA, through its wholly-owned subsidiary, Walgreen Co., is making a majority investment in Shields, an industry leader in integrated, health system-owned specialty pharmacy care.

Key Points: 
  • Walgreens Boots Alliance, Inc. (Nasdaq: WBA) and Shields Health Solutions today announced that WBA, through its wholly-owned subsidiary, Walgreen Co., is making a majority investment in Shields, an industry leader in integrated, health system-owned specialty pharmacy care.
  • The approximately $970 million investment will support the continued growth of Shields health system-based specialty pharmacy strategy, and builds on a minority equity investment that WBA announced in July 2019.
  • The Shields model has shown to improve patient care, and will be complementary to our existing specialty pharmacy offering, further expanding our capabilities to best meet the needs of health system partners and patients.
  • Shields pioneered the integrated, health system specialty pharmacy approach that has quickly gained traction in the industry.